Purpose of review Multidrug-resistant
bacteria infections are listed among the top public health threats of the current era. As a result, there has been an increase in efforts to develop new therapeutic agents against MDR Gram-negatives. The purpose of this review is to summarize the clinical and preclinical findings associated with recently approved drugs and the drugs in clinical development against ESBL and carbapenemase-producing Enterobacterales, carbapenem-resistant Pseudomonas aeruginosa
and carbapenem-resistant Acinetobacter baumannii
There are a number of ESBL active agents in late stage clinical development that can help spare carbapenems. Likewise, recently approved β-lactam/β-lactamase inhibitor
combinations allow a change in the treatment of KPC and OXA-48 producers and carbapenem-resistant P. aeruginosa
from colistin to new, safer agents. Treatment of Meta-beta-lactamase (MBL) producers remains an unmet need – apart from cefiderocol, most agents with MBL activity are still in clinical development. Among the few agents with carbapenem-resistant A. baumannii
activity, durlobactam/sulbactam in phase III clinical trials provides hope.
Armamentarium against MDR Gram-negatives has expanded with the dominance of agents active against ESBL and KPC producers. There is a need to prioritize MBL producers and carbapenem-resistant A. baumannii
, as well as the need for clinical trials to test the new agents against serious infections.